SG Americas Securities LLC Acquires 18,180 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

SG Americas Securities LLC boosted its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by 57.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 49,673 shares of the biotechnology company’s stock after purchasing an additional 18,180 shares during the period. SG Americas Securities LLC’s holdings in Rigel Pharmaceuticals were worth $72,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC increased its position in shares of Rigel Pharmaceuticals by 100.0% during the second quarter. Integrated Wealth Concepts LLC now owns 20,000 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 10,000 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Rigel Pharmaceuticals by 78.1% during the second quarter. Tower Research Capital LLC TRC now owns 21,694 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 9,514 shares during the period. State of Wyoming bought a new stake in shares of Rigel Pharmaceuticals during the fourth quarter valued at approximately $33,000. Balyasny Asset Management LLC bought a new stake in shares of Rigel Pharmaceuticals during the third quarter valued at approximately $34,000. Finally, UBS Group AG bought a new stake in shares of Rigel Pharmaceuticals during the fourth quarter valued at approximately $35,000. 66.23% of the stock is owned by institutional investors.

Rigel Pharmaceuticals Stock Performance

Rigel Pharmaceuticals stock opened at $1.08 on Friday. The firm has a market cap of $189.44 million, a P/E ratio of -7.20 and a beta of 0.95. The business’s fifty day moving average is $1.34 and its two-hundred day moving average is $1.19. Rigel Pharmaceuticals, Inc. has a 52 week low of $0.71 and a 52 week high of $1.96.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Cantor Fitzgerald boosted their price objective on Rigel Pharmaceuticals from $2.00 to $3.00 and gave the company a “neutral” rating in a research report on Wednesday, March 6th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Rigel Pharmaceuticals in a research note on Wednesday, March 6th. Citigroup boosted their price target on Rigel Pharmaceuticals from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Thursday, March 7th. StockNews.com lowered Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 4th. Finally, B. Riley reaffirmed a “neutral” rating and issued a $1.25 price target on shares of Rigel Pharmaceuticals in a research note on Wednesday, March 6th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Rigel Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $5.81.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.